Sanofi Says FDA Approves Sarclisa Escena SC As First Anticancer Treatment Via On-body Injector

Sanofi said the FDA approved subcutaneous Sarclisa Escena delivered via the CirCLIQ on-body injector for multiple myeloma patients. The approval is a meaningful regulatory win that supports broader, more convenient administration compared with existing options.

Analysis

Sanofi said the FDA approved subcutaneous Sarclisa Escena delivered via the CirCLIQ on-body injector for multiple myeloma patients. The approval is a meaningful regulatory win that supports broader, more convenient administration compared with existing options.